BV 63072
Alternative Names: bisphosphonate-sitafloxacin conjugate; BP-sitafloxacin conjugate; BV-63072; OsteoFloxacin™Latest Information Update: 19 Feb 2026
At a glance
- Originator BioVinc
- Class Anti-inflammatories; Antibacterials; Drug conjugates; Fluoroquinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Osteomyelitis
Most Recent Events
- 05 Sep 2025 Preclinical trials in Osteomyelitis in USA (IV) prior to September 2025
- 05 Sep 2025 Pharmacokinetics data from a preclinical studies in Osteomyelitis presented at the Annual Meeting of the American Society for Bone and Mineral Research 2025 (ASBMR-2025)
- 15 Dec 2020 BioVinc has patent protection for 'Bisphosphonate quinolone conjugates and uses thereof' in USA